NCT04598607View on ClinicalTrials.gov

Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

January 11, 2021

Study Completion Date

January 15, 2021

Conditions
Major Depressive Disorder
Interventions
DRUG

Hypidone Hydrochloride tablets

30mg(10mg×3), 40mg(10mg×4) or 50mg(10mg×5) Hypidone Hydrochloride tablets will be given orally once on day 1, day 9 and twice a day on day 3\~8.

DRUG

Placebo

3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.

Trial Locations (1)

200030

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Zhejiang Huahai Pharmaceutical Co., Ltd.

INDUSTRY

NCT04598607 - Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects | Biotech Hunter | Biotech Hunter